Resistell AG

Based in Switzerland, Resistell AG focuses on developing innovative antibiotic susceptibility testing solutions, utilizing its proprietary nanomotion technology for rapid diagnostics in healthcare settings. Founded in 2018 in Basel, Switzerland, Resistell AG specializes in advanced antibiotic susceptibility testing. The company has completed 6 deals, with its most recent funding round being Series B, which raised CHF 8. 5 million on December 20, 2022.

The funding included participation from the European Innovation Council, Occident Group, TRUMPF Venture, Zürcher Kantonalbank, and bp Launchpad. Danuta Cichocka serves as both CEO and founder, bringing her expertise in healthcare technology to lead the company's operations. Resistell specializes in the development and commercialization of advanced antibiotic susceptibility testing (AST) solutions, focusing on its proprietary nanomotion technology. Their core product, the Phenotech platform, enables ultra-rapid testing of bacterial sensitivity to antibiotics by detecting nanoscale vibrations produced by living bacterial cells.

This innovative method significantly reduces the time required for results compared to traditional culture-based antibiograms, shortening it from days to just a few hours. The technology is primarily intended for use in clinical laboratories and hospitals, aiding healthcare providers in identifying effective antibiotics for treating bacterial infections and addressing the critical issue of antibiotic resistance. Resistell's products are marketed in Switzerland and international markets, targeting healthcare institutions across Europe with potential expansion to other regions globally. Resistell's revenue model is based on partnerships and direct sales targeting healthcare institutions such as hospitals and diagnostic laboratories.

The company engages in transactions with clients, providing access to its nanomotion technology and AST solutions through outright purchases or subscription-based services. These transactions typically involve deploying the Phenotech platform within clinical settings, allowing users to conduct rapid antibiotic susceptibility tests. As clients use Resistell's products, they experience improved patient outcomes and reduced healthcare costs associated with antibiotic-resistant infections, supported by a financial structure designed for ongoing support and maintenance in real-time clinical scenarios. In December 2022, Resistell AG raised CHF 8.

5 million in Series B funding, which will be used to complete clinical trials for antibiotic susceptibility testing and to support the market entry of its R&D device, Phenotech Research. The company plans to introduce new products and expand its market presence, specifically targeting healthcare institutions in additional regions by 2024.